NT5E CpG island methylation is a favourable breast cancer biomarker

BACKGROUND: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5′-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. METHODS: We used RT–...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Nigro, C, Monteverde, M, Lee, S, Lattanzio, L, Vivenza, D, Comino, A, Syed, N, McHugh, A, Wang, H, Proby, C, Garrone, O, Merlano, M, Hatzimichael, E, Briasoulis, E, Gojis, O, Palmieri, C, Jordan, L, Quinlan, P, Thompson, A, Crook, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389412/
https://www.ncbi.nlm.nih.gov/pubmed/22653144
http://dx.doi.org/10.1038/bjc.2012.212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389412/
https://www.ncbi.nlm.nih.gov/pubmed/22653144
http://dx.doi.org/10.1038/bjc.2012.212

Ejemplares similares